

30th July, 2026

To,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

Dear Sir,

Sub: Outcome of the Board Meeting
BSE Code: 531210

The Meeting of Board of Directors was held on Thursday, 30th July, 2026 at 03:30 p.m. The Board of Directors discussed and/or approved the following:

1. The Board considered and approved Un-Audited Financial Results for the quarter ended 30th June, 2026 as per Regulation 33 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In this regard, the Statutory Auditors have carried out "Limited Review" of the above results.
Please find enclosed copy of unaudited financial results along with Limited Review Report for the quarter ended 30th June, 2026.
2. The Board approved Director's Report for the year ended 31st March, 2026.
3. The Board also approved Management Discussion Report, Corporate Governance Report, CEO's certification & other documents for the year ended 31st March, 2026.
4. The Board took note of the Secretarial Audit Report issued by M/s. Sanjay Dholakia & Associates, Practising Company Secretaries for the year ended 31st March, 2026.
5. The Board considered and approved the appointment of Mrs. Vijaya Mani (DIN 11363910) as Director (Promoter & Non-Executive) of the Company, liable to retire by rotation, with effect from the forthcoming Annual General Meeting, subject to the approval of the members at the said Annual General Meeting. The Board accordingly recommended her appointment for the approval of the members.
6. The Board discussed, approved and recommended the appointment of Mr. N. K. Menon as Whole time Director and CEO for further term of 1 year w.e.f 1st October, 2026 to 30th September, 2027 subject to approval of members in the forthcoming Annual General Meeting.
7. The Board discussed and finalized the date, time and mode of 40th Annual General Meeting of the Company on Tuesday, 22nd September, 2026, at 2.30 P. M. through video conference or other audio-visuals means and also approved the draft notice of forthcoming Annual General Meeting of the Company.

Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400078 INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123



8. The Board also approved and finalized that the Register of Members will remain closed for the purpose of 40th Annual General Meeting of the Company from 15th September, 2026 to 22nd September, 2026 (both days inclusive).
9. Further pursuant to Rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed 15th September, 2026 as the Cut-Off date for the purpose of determining the eligible shareholders (holding shares either in physical form or in dematerialized form) to cast their votes electronically between 19th September, 2026 (9:30 A.M. IST) to 21st September, 2026(5:00 P.M. IST).
10. The Board also considered and approved appointment of M/s. Sanjay Dholakia & Associates, Practising Company Secretaries as the Secretarial Auditor for the financial year ended 31st March, 2027.
11. The Board also considered and approved appointment of CA Ajay Ramsevak Sharma., Chartered Accountant, (Firm Reg. no. 137003W) as an Internal Auditor of the Company for the Financial Year 2026-27;

Additionally, disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with circular SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated July 13, 2023 is attached as **Annexure-A, Annexure- B & Annexure-C.**

The Board Meeting commenced at 3:30 p.m. and concluded at 5.30 p.m.

This is for your information and record.

Thanking you,

Yours faithfully,

FOR COLINZ LABORATORIES LTD

VIJAYA MANI
DIRECTOR
DIN : 11363910



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123

Annexure-A

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023.

Annexure -A S. No.	Particulars	Description
1.	Reason for Change Viz., Appointment, Resignation, removal, death or otherwise;	Appointment: to comply with the Companies Act, 2013 and the requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2.	Date of Appointment/Cessation (as applicable) & terms of appointment	Date: 30 July, 2026. M/s. Sanjay Dholakia & Associates, Practising Company Secretaries is appointed as Secretarial Auditor of the Company for F.Y 2026-27.
3.	Brief profile (in case of appointment)	Name of Auditor: M/s. Sanjay Dholakia & Associates, Practising Company Secretaries. Office Address: GP 15, 2nd. Floor, Raghuleela Mall,Behind Poinsur Bus Depot, Kandivali(W),Mumbai 400067 Email id: <u>sanjayrd65@gmail.com</u> Field of Experience: M/s. Sanjay Dholakia & Associates, Practising Company Secretaries (Membership No 2655 CP 1798) based in Mumbai. The Proprietor of the Firm Mr. Sanjay Dholakia possesses experience in the field of Company Law, Secretarial Work, Due Diligence, SEBI Regulation, Dispute Resolution, Intellectual Property, Trademarks, Legal Process, Litigation, Legal compliance, and Securities Regulation.
4.	Disclosure of relationships between directors (in case of appointment of a director).	NA

Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078 INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123



Annexure-B

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023.

Annexure -A S. No.	Particulars	Description
1.	Reason for Change Viz., Appointment. Resignation, removal, death or otherwise;	Appointment: to comply with the Companies Act, 2013 and the requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2.	Date of Appointment/Cessation (as applicable) & terms of appointment	Date: 30 July, 2026. CA Ajay Ramsevak Sharma. (FRN. 137003W) is appointed as Internal Auditor of the Company for F.Y 2026-27.
3.	Brief profile (in case of appointment)	Name of Auditor: Ca Ajay Ramsevak Sharma. Office Address: Flat No 203, C Wing, Green park , Lodha Heritage, Desalepada, Dombivali East, Thane -421201 Email id: caajaysharma88@gmail.com Field of Experience: M/s. Ajay Sharma & Associates, Chartered Accountant is a member of the Institute of Chartered Accountants of India (ICAI) having working experience and proficiency in matters related to Audit, Certification and Compliances in areas such as Statutory Audit, Tax audit, GST Audit, etc.
4.	Disclosure of relationships between directors (in case of appointment of a director).	NA



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123

Annexure-C

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023.

Name of Director	Mr. N. K. Menon (DIN 01111297)	Mrs. Vijaya Mani (DIN: 11363910)
Reason for Change Viz., Appointment, Resignation, removal, death or otherwise;	Based on the recommendation of the Nomination and Remuneration Committee the Board of Directors have approved the appointment of Mr. N. K. Menon (DIN 01111297), as an Whole Time Director & Chief Executive Officer, liable to retire by rotation on the Board of Directors of the Company for a term of One (1) years	Based on the recommendation of the Nomination and Remuneration Committee the Board of Directors have approved the appointment of Mrs. Vijaya Mani (DIN: 11363910) , as a Director in the category of Promoter & Non-Executive Director.
Date of Appointment/Cessation (as applicable) & terms of appointment	Appointment for the term of One year with effect from 1st October, 2026 till 30th September, 2027	Appointment will be effective from 22nd September, 2026 till 30th September, 2027 subject to members in the forthcoming Annual General Meeting.
Brief profile (in case of appointment)	Material Management, Factory Management, General Administration	Strategic Planning & Leadership, Operations & Governance
Disclosure of relationships between directors (in case of appointment of a director).	Mr. N. K. Menon is not related to any Directors of the Company.	Mrs. Vijaya Mani is not related to any Directors of the Company.
Person shall not be debarred from holding the office of Director pursuant to any SEBI order	Mr. N. K. Menon is not debarred from holding the office of Director of the Company by virtue of any SEBI Order or any other authority	Mrs. Vijaya Mani is not debarred from holding the office of Director of the Company by virtue of any SEBI Order or any other authority.



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Independent Auditor's Review Report on Unaudited Quarterly Financial Results

To
The Board of Directors,
COLINZ LABORATORIES LIMITED.


We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **COLINZ LABORATORIES LIMITED** ('the Company') for the quarter ended 30th June, 2026 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34') prescribed u/s 133 of the Companies Act, 2013 ('the Act'), SEBI Circular CIR/CF/FAC/62/2016 dated 05/07/2016 (hereinafter referred to as the 'the SEBI Circular') and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Statements Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Act read with relevant Rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VORA & ASSOCIATES
CHARTERED ACCOUNTANTS
(ICAI Firm Reg. No.: 111612W)



RONAK A. RAMBHIA
PARTNER

(Membership No.: 140371)

UDIN: 26140371HVSVXR8074
PLACE: MUMBAI
DATED: July 30, 2026

COLINZ LABORATORIES LIMITED.

(CIN NO : L24200MH1986PLC041128)

A-101, Pratik Industrial Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2026

"(Rs. In Lakhs)"

S. No.	Particulars	Un-Audited		Audited	Audited
		Quarter ended			Year Ended
		30-Jun-26	30-Jun-25	31-Mar-26	31-Mar-26
PART -I					
1	(a)Revenue from Operation	124.09	156.61	174.79	613.61
3	(b) Other Income	12.17	7.52	17.45	48.44
3	Total Income from Operation	136.26	164.13	192.24	662.05
4	Expenses				
	(a) Cost Of Material Consumed	10.93	18.73	11.37	57.05
	(b) Purchase of Stock in Trade	30.06	42.68	25.73	112.48
	(c) Change in Inventories Of Finished Goods and Work in Progress and Stock in Trade	(18.80)	(21.44)	21.14	1.50
	(d) Employee Benefit Expenses	63.58	65.71	69.50	269.56
	(e) Finance Cost	0.73	1.16	1.05	4.66
	(f) Depreciation & Amortisation Expenses	3.91	3.91	3.91	15.63
	(g) Other Expenses	32.06	37.31	37.96	132.26
	Total Expenses	122.47	148.06	170.66	593.14
5	Profit /(Loss) Before exceptional items and tax (3-4)	13.79	16.07	21.58	68.91
6	Exceptional items	-	-	-	-
	i) Profit on Sale of Fixed Assets (net)	276.33	-	-	-
7	Profit /(Loss) before tax (5-6)	290.12	16.07	21.58	68.91
8	Tax Expenses (Provision for Taxation) Current tax				
	i) Current Tax	50.00	4.15	6.00	19.00
	ii) Deffered Tax	-	-	(1.54)	(1.54)
	iii) Tax for earlier years	-	-	-	-
9	Profit /(Loss) for the period from continuing operations(7-8)	240.12	11.92	17.12	51.45
10	Profit /(Loss) for the period	240.12	11.92	17.12	51.45
11	Other Comprehensive Income (Net of Tax)				
	A) Item that will not be reclassified to Profit or Loss Account				
	i) Change in fair value of investment in Equity Instruments	13.66	9.13	(16.79)	5.42
12	Total Comprehensive Income for the period (10+11) Comprising	253.78	21.05	0.33	56.87
13	Earning per equity share (for Continuing operation) (In Rs.)				
	i) Basic	9.53	0.47	0.68	2.04
	ii) Diluted	9.53	0.47	0.68	2.04



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128



Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123

NOTES TO THE FINANCIAL RESULTS :-

- 1) The above un-Audited financial statement for quarter ended June 30, 2026 has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 30th July, 2026 and Statutory Auditors of the Company have carried out limited review audit of the same.
- 2) The Company is primarily engaged in the business of manufacturing Pharmaceutical Formulations and there is no other reportable segment.
- 3) During the quarter, the Company has received the second and final tranche of proceeds from the sale of factory land and building and machinery at Sinnar, Maharashtra. However, the manufacturing activities of the factory are continuing on loan license/ third party basis..
- 4) Previous period figures have been regrouped/ rearranged / reclassified, wherever necessary.
- 5) In accordance with regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulation,2015, The Un-Audited Results for Quarter and period ended 30th June,2026 are available on the BSE website (URL: www.bselindia.com) and the Company's website (URL: www.findoc-cll.in).

Place : Mumbai
Date : 30-07-2026

For and on behalf of the Board
COLINZ LABORATORIES LTD.
CIN NO : L24200MH1986PLC041128

Vijaya Mani

Chairman of the Meeting



Colinz Laboratories Limited
CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123